On 23 April 2020, a presentation at the American Academy of Managed Care Pharmacy eLearning Days discussed future biosimilar launches in the US. A particular emphasis was placed on the number of adalimumab biosimilars waiting to come to market, with competition in this space expected to heat up in 2023. Possible biosimilar launches for 2020 which were discussed include pegfilgrastim, bevacizumab and rituximab.
Soft Close, Hard Lessons: Full Court Reinforces Purposive Construction of Patent Claims and the Disclosure Requirements for Divisional Patents
Glass Hardware Australia Pty Ltd v TCT Group Pty Ltd [2024] FCAFC 95 Date of decision: 17 July 2024 Body: Full Court of the Federal Court of...